Who Owns Cosentyx?

• Parent Company: Novartis
• Ownership Type: Brand division
• Company Type: Publicly Traded
• Stock Ticker: SIX: NOVN

• Founded: 2015
• Founders: Novartis (internal development)

• Founded: 1996
• Headquarters: Basel, Switzerland
• Company Type: Publicly Traded
• Stock: SIX: NOVN
• Revenue: approximately $50.3 billion (FY2024)
• Employees: Approximately 100,000

Visit Novartis website

• Headquarters: Basel, Switzerland
• Manufacturing / Operations: Switzerland, Germany, United States

Cosentyx operates under Novartis' comprehensive sustainability framework, which addresses environmental responsibility, ethical business practices, and social impact within the pharmaceutical industry. As a biologic medication treating autoimmune diseases, Cosentyx's sustainability efforts focus on responsible manufacturing, environmental stewardship, and healthcare accessibility.

Environmental Manufacturing and Green Chemistry: Cosentyx manufacturing facilities implement comprehensive sustainability measures including reduced water usage, energy-efficient production processes, and waste reduction programs. The company has invested in green chemistry principles that minimize environmental impact while maintaining biologic drug quality and efficacy. Cosentyx's manufacturing sites maintain ISO 14001 environmental management certification and work toward carbon neutrality goals while meeting pharmaceutical industry standards for clean room operations and biologic production.

Sustainable Product Development: Cosentyx has implemented sustainable development practices that minimize environmental impact while maintaining therapeutic effectiveness. The company's biologic drug development process includes environmental risk assessments, green chemistry principles, and lifecycle assessments to reduce environmental footprint. Cosentyx's formulation scientists focus on creating effective treatments while minimizing environmental impact through sustainable material selection and process optimization.

Responsible Supply Chain Management: Cosentyx maintains strict ethical sourcing standards for raw materials and components used in biologic manufacturing. The company works with suppliers who demonstrate commitment to environmental regulations, ethical labor practices, and sustainable practices. Cosentyx conducts regular supplier audits and maintains comprehensive documentation of supply chain sustainability practices, ensuring ethical business relationships throughout its pharmaceutical manufacturing network.

Environmental Risk Assessment: Cosentyx maintains comprehensive environmental risk assessments for its active pharmaceutical ingredients and manufacturing processes. The company evaluates potential environmental impact throughout the product lifecycle, from raw material sourcing to patient use and disposal. Cosentyx's environmental risk assessments include water usage, energy consumption, and potential ecosystem impact assessments that inform sustainability initiatives.

Healthcare Accessibility: Cosentyx participates in Novartis's initiatives focused on improving healthcare accessibility and affordability. The company supports programs that provide medication access to underserved populations, patient education programs, and healthcare infrastructure development. Cosentyx's global reach and Novartis's pricing strategies help improve access to biologic treatments for autoimmune conditions in developing markets.

Patient Safety and Ethical Clinical Practices: Cosentyx maintains strict ethical standards for clinical trials, data privacy, and patient safety. The company's clinical development programs include comprehensive safety monitoring, adverse event reporting, and patient education programs. Cosentyx's commitment to ethical clinical practices includes transparent reporting of clinical trial results and maintaining patient confidentiality.

Community Engagement and Education: Cosentyx participates in Novartis's community initiatives focused on autoimmune disease awareness, patient education, and healthcare professional training. The company supports programs that provide education about autoimmune diseases, treatment options, and living with chronic conditions. Cosentyx's community engagement programs include partnerships with patient advocacy groups and healthcare organizations.

Climate Action and Carbon Reduction: Cosentyx contributes to Novartis' climate action goals by reducing greenhouse gas emissions across its operations. The company has implemented measures to reduce carbon emissions in manufacturing, transportation, and distribution. Cosentyx works with suppliers to reduce carbon emissions throughout the supply chain and invests in renewable energy and carbon offset programs to achieve carbon neutrality targets.

Regulatory Compliance and Ethics: Cosentyx maintains strict compliance with all relevant regulations governing pharmaceutical development and marketing in the markets where it operates. The company's compliance programs ensure adherence to FDA, EMA, and other international regulatory requirements while maintaining high ethical standards in clinical research and marketing practices.

Cosentyx has received recognition within the pharmaceutical industry for its innovation in biologic drug development, clinical efficacy, and market leadership in treating autoimmune diseases, particularly psoriasis and psoriatic arthritis. As Novartis's flagship immunology biologic, Cosentyx's accolades are often attributed to the parent company's overall pharmaceutical portfolio.

FDA Innovation Recognition: Cosentyx received FDA Breakthrough Therapy designation in 2015 for treating moderate to severe plaque psoriasis, acknowledging its innovation in biologic drug development. This recognition highlighted Cosentyx's novel mechanism of action targeting the IL-17 pathway and its potential to transform psoriasis treatment paradigms.

Clinical Excellence Awards: Cosentyx has received recognition from dermatology organizations and medical publications for its clinical trial results and therapeutic efficacy in treating various autoimmune conditions. The company's clinical development programs have been acknowledged for rigorous scientific methodology, comprehensive safety monitoring, and meaningful clinical outcomes in psoriasis and psoriatic arthritis treatment.

Market Leadership Recognition: Cosentyx has been acknowledged by market research organizations for its strong performance in the biologic immunology market. The company's 25% sales growth in 2024 and projected market value reaching $9.51 billion by 2030 has been recognized by pharmaceutical industry analysts for exceptional growth in the competitive biologic market segment.

Scientific Innovation Recognition: Cosentyx's development of IL-17 pathway inhibition technology has been acknowledged by pharmaceutical research organizations and immunology societies for innovation in biologic drug mechanisms. The company's approach to targeting specific inflammatory pathways has been acknowledged for advancing scientific understanding of autoimmune disease treatment.

Patient Advocacy Recognition: Cosentyx's patient education programs and support initiatives have been recognized by patient advocacy organizations for improving understanding of autoimmune diseases and treatment options. The company's comprehensive patient education materials and support programs have been acknowledged for empowering patients with information about their conditions.

Regulatory Achievement Recognition: Cosentyx's successful navigation of the FDA approval process and international regulatory approvals has been acknowledged by regulatory affairs organizations for excellence in regulatory compliance and clinical trial management.

Healthcare Industry Leadership: Cosentyx has been recognized by healthcare industry organizations for its role in advancing biologic treatments for autoimmune diseases. The company's market leadership in the psoriasis and psoriatic arthritis segments has been acknowledged by healthcare publications and industry associations.

Cosentyx has maintained a relatively clean operational record throughout its history since FDA approval in 2015, with no major product recalls or significant controversies that have substantially damaged the brand's reputation or standing in the pharmaceutical industry.

Product Safety Record: Cosentyx has maintained strong product safety standards throughout its history, with no major product recalls or safety incidents reported. The company's biologic drug undergoes rigorous testing and quality control processes to ensure it meets safety standards for biologic medications. Cosentyx's commitment to product safety has helped maintain healthcare provider trust and brand reputation in the competitive biologic market.

Regulatory Compliance: Cosentyx has maintained compliance with all relevant regulations governing biologic medications in the markets where it operates. The company has not faced significant regulatory actions or compliance violations that have resulted in fines or operational restrictions. Cosentyx's proactive approach to regulatory compliance has prevented major legal challenges.

Clinical Trial Ethics: Cosentyx has maintained strict ethical standards for clinical trials, patient safety, and data privacy. The company's clinical development programs include comprehensive informed consent processes, safety monitoring, and adverse event reporting. Cosentyx's commitment to ethical clinical practices has maintained high standards in pharmaceutical research and development.

Pricing and Accessibility Concerns: Cosentyx faces challenges related to high pricing and accessibility as a biologic medication. The high cost of biologic treatments has raised concerns about healthcare equity and patient access, particularly in developing markets. These concerns have led to discussions about healthcare policy and insurance coverage for biologic medications.

Side Effect Management: Cosentyx has faced scrutiny regarding potential side effects and safety concerns, particularly concerning immune suppression and infection risk. The company has addressed these concerns through comprehensive safety monitoring, patient education, and clear communication about potential risks and benefits.
Competition and Market Pressure: Cosentyx faces increasing competition from other biologic medications and new treatment approaches in the autoimmune disease market. These competitive challenges represent normal market dynamics rather than ethical or operational controversies.

Insurance Coverage Challenges: Cosentyx's high cost has created challenges for patient access through insurance coverage, with varying coverage policies across different healthcare systems. These challenges represent broader healthcare system issues rather than brand-specific controversies.

Supply Chain Management: Cosentyx has maintained ethical supply chain practices throughout its operations, working with suppliers who meet environmental and labor standards. The company has not faced significant controversies related to supply chain practices or manufacturing ethics.

Global Market Adaptation: Cosentyx has faced challenges related to adapting to different healthcare systems, regulatory requirements, and market access strategies across international markets. These challenges have been addressed through localized market approaches and regulatory compliance programs.